& Gerich, J
semaglutide comparison offers information to help you decide: While AOD9604 targets fat metabolism with minimal side effects, it lacks regulatory approval
To date, these GLP-1 drugs have been approved to treat three adult populations: individuals with type 2 diabetes, individuals with a body mass index (BMI) of 30 or greater (obesity), and individuals with a BMI between 27 and 30 (overweight) with at least one weight-related health condition, such as cardiovascular disease, high blood pressure, high cholesterol, prior stroke, prior heart attack, and chest pain (angina)
Common side effects of Saxenda include nausea, diarrhea, constipation, vomiting, injection site reaction, low blood sugar, headache, fatigue, dizziness, stomach pain, and changes in enzyme levels in the blood
Have another question about TB-500 5mg + BPC-157 5mg, Research Peptide Canada